Synergia Medical

Synergia Medical operates in the medical-device and neurostimulation segment, with a focused approach built around optoelectronics rather than conventional electrical stimulation interfaces. Its flagship NAO.VNS™ device is described as an implantable vagus nerve stimulation system with MRI compatibility and electromagnetic-interference immunity, targeting drug-resistant epilepsy. The company’s profile is that of a privately held, small Belgian specialist with an employee range of 11–50 and a reported team of thirteen highly skilled multidisciplinary professionals during an earlier development stage. Its €10.6 million in disclosed financing, including a €8.1 million Series A and a €2.5 million grant, provided support for implantable-neurostimulator development. The 2024–2025 implantation announcements improve its credibility as a clinical-stage developer, but the absence of disclosed valuation, revenue, regulatory approvals, or large-scale commercialization makes its market position difficult to quantify.

Synergia Medical’s trajectory shows a progression from technical formation to early human clinical validation. Founded in 2013, the company reports that it became ISO 13485 certified within three years, created and sold an OEM external neurostimulator for a motorized amputee prosthesis arm, and developed the first version of its NAOS platform. Financing then accelerated product development: a $10,044,331 Series A was announced on Feb 19, 2018, followed by a $2,614,423 European Innovation Council grant on Jun 15, 2022. The company’s disclosed funding total is $12,658,754 across two rounds. Patent activity in 2022 and 2023 addressed implant depth measurement and power-consumption optimization, indicating continued work on implant architecture. The next clear inflection point came in September 2024, when first NAO.VNS™ patients were implanted. By January 2025, five patients had been implanted, and Charles Nolet replaced Attila Borbath as CEO on Feb 1, 2025. Strong first-in-human study results were announced on Feb 24, 2025.